Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8187 |
Intermediate Similarity |
NPD5684 |
Clinical (unspecified phase) |
0.8187 |
Intermediate Similarity |
NPD5682 |
Phase 3 |
0.8187 |
Intermediate Similarity |
NPD5683 |
Clinical (unspecified phase) |
0.7895 |
Intermediate Similarity |
NPD3107 |
Discontinued |
0.7886 |
Intermediate Similarity |
NPD3083 |
Approved |
0.7861 |
Intermediate Similarity |
NPD2646 |
Discontinued |
0.7738 |
Intermediate Similarity |
NPD249 |
Approved |
0.7738 |
Intermediate Similarity |
NPD250 |
Approved |
0.7654 |
Intermediate Similarity |
NPD1777 |
Approved |
0.7654 |
Intermediate Similarity |
NPD1776 |
Approved |
0.7647 |
Intermediate Similarity |
NPD195 |
Approved |
0.7647 |
Intermediate Similarity |
NPD186 |
Discovery |
0.7586 |
Intermediate Similarity |
NPD1369 |
Phase 2 |
0.7557 |
Intermediate Similarity |
NPD2624 |
Phase 2 |
0.7556 |
Intermediate Similarity |
NPD7988 |
Suspended |
0.7543 |
Intermediate Similarity |
NPD339 |
Approved |
0.75 |
Intermediate Similarity |
NPD5666 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD169 |
Phase 2 |
0.7486 |
Intermediate Similarity |
NPD1750 |
Clinical (unspecified phase) |
0.7486 |
Intermediate Similarity |
NPD338 |
Approved |
0.7471 |
Intermediate Similarity |
NPD283 |
Approved |
0.7418 |
Intermediate Similarity |
NPD2647 |
Phase 3 |
0.7412 |
Intermediate Similarity |
NPD185 |
Approved |
0.7386 |
Intermediate Similarity |
NPD242 |
Approved |
0.736 |
Intermediate Similarity |
NPD1732 |
Phase 3 |
0.7356 |
Intermediate Similarity |
NPD548 |
Clinical (unspecified phase) |
0.7326 |
Intermediate Similarity |
NPD166 |
Approved |
0.7294 |
Intermediate Similarity |
NPD193 |
Suspended |
0.724 |
Intermediate Similarity |
NPD6417 |
Clinical (unspecified phase) |
0.7216 |
Intermediate Similarity |
NPD3708 |
Phase 2 |
0.7181 |
Intermediate Similarity |
NPD4171 |
Clinical (unspecified phase) |
0.7126 |
Intermediate Similarity |
NPD7158 |
Phase 1 |
0.7113 |
Intermediate Similarity |
NPD7138 |
Phase 2 |
0.7072 |
Intermediate Similarity |
NPD216 |
Approved |
0.7072 |
Intermediate Similarity |
NPD220 |
Clinical (unspecified phase) |
0.7072 |
Intermediate Similarity |
NPD217 |
Approved |
0.7072 |
Intermediate Similarity |
NPD218 |
Approved |
0.7072 |
Intermediate Similarity |
NPD219 |
Phase 3 |
0.6979 |
Remote Similarity |
NPD4716 |
Approved |
0.6978 |
Remote Similarity |
NPD546 |
Clinical (unspecified phase) |
0.6963 |
Remote Similarity |
NPD1412 |
Clinical (unspecified phase) |
0.6943 |
Remote Similarity |
NPD4744 |
Clinical (unspecified phase) |
0.6906 |
Remote Similarity |
NPD213 |
Clinical (unspecified phase) |
0.6906 |
Remote Similarity |
NPD214 |
Approved |
0.6898 |
Remote Similarity |
NPD247 |
Clinical (unspecified phase) |
0.6864 |
Remote Similarity |
NPD248 |
Discontinued |
0.68 |
Remote Similarity |
NPD3695 |
Approved |
0.68 |
Remote Similarity |
NPD3696 |
Approved |
0.678 |
Remote Similarity |
NPD4240 |
Approved |
0.6754 |
Remote Similarity |
NPD8291 |
Clinical (unspecified phase) |
0.6734 |
Remote Similarity |
NPD2632 |
Approved |
0.6734 |
Remote Similarity |
NPD2631 |
Clinical (unspecified phase) |
0.6734 |
Remote Similarity |
NPD2630 |
Approved |
0.6701 |
Remote Similarity |
NPD1692 |
Approved |
0.6681 |
Remote Similarity |
NPD8375 |
Approved |
0.6623 |
Remote Similarity |
NPD8371 |
Clinical (unspecified phase) |
0.6612 |
Remote Similarity |
NPD7842 |
Phase 2 |
0.6596 |
Remote Similarity |
NPD516 |
Clinical (unspecified phase) |
0.657 |
Remote Similarity |
NPD9632 |
Phase 3 |
0.655 |
Remote Similarity |
NPD870 |
Clinical (unspecified phase) |
0.6524 |
Remote Similarity |
NPD2965 |
Clinical (unspecified phase) |
0.6517 |
Remote Similarity |
NPD549 |
Approved |
0.6512 |
Remote Similarity |
NPD9633 |
Phase 3 |
0.6477 |
Remote Similarity |
NPD252 |
Clinical (unspecified phase) |
0.6453 |
Remote Similarity |
NPD4054 |
Clinical (unspecified phase) |
0.6415 |
Remote Similarity |
NPD2876 |
Phase 3 |
0.6415 |
Remote Similarity |
NPD2877 |
Clinical (unspecified phase) |
0.6389 |
Remote Similarity |
NPD2902 |
Phase 2 |
0.6389 |
Remote Similarity |
NPD2903 |
Clinical (unspecified phase) |
0.6355 |
Remote Similarity |
NPD2824 |
Phase 2 |
0.6338 |
Remote Similarity |
NPD7323 |
Phase 2 |
0.6337 |
Remote Similarity |
NPD9408 |
Phase 3 |
0.6316 |
Remote Similarity |
NPD4074 |
Clinical (unspecified phase) |
0.6304 |
Remote Similarity |
NPD7531 |
Clinical (unspecified phase) |
0.6298 |
Remote Similarity |
NPD1430 |
Approved |
0.6298 |
Remote Similarity |
NPD1431 |
Approved |
0.629 |
Remote Similarity |
NPD3085 |
Phase 1 |
0.6273 |
Remote Similarity |
NPD5080 |
Phase 2 |
0.6257 |
Remote Similarity |
NPD3086 |
Phase 3 |
0.6245 |
Remote Similarity |
NPD6023 |
Discontinued |
0.6236 |
Remote Similarity |
NPD194 |
Clinical (unspecified phase) |
0.6227 |
Remote Similarity |
NPD5079 |
Phase 2 |
0.6223 |
Remote Similarity |
NPD536 |
Clinical (unspecified phase) |
0.6223 |
Remote Similarity |
NPD9605 |
Phase 3 |
0.6209 |
Remote Similarity |
NPD5665 |
Clinical (unspecified phase) |
0.6175 |
Remote Similarity |
NPD582 |
Approved |
0.6133 |
Remote Similarity |
NPD1808 |
Phase 1 |
0.6089 |
Remote Similarity |
NPD1046 |
Clinical (unspecified phase) |
0.6075 |
Remote Similarity |
NPD1730 |
Discontinued |
0.6053 |
Remote Similarity |
NPD231 |
Clinical (unspecified phase) |
0.6026 |
Remote Similarity |
NPD8409 |
Suspended |
0.6022 |
Remote Similarity |
NPD171 |
Discontinued |
0.6022 |
Remote Similarity |
NPD1121 |
Approved |
0.6022 |
Remote Similarity |
NPD1120 |
Approved |
0.6009 |
Remote Similarity |
NPD6840 |
Approved |
0.6 |
Remote Similarity |
NPD4459 |
Clinical (unspecified phase) |
0.6 |
Remote Similarity |
NPD4495 |
Phase 1 |
0.6 |
Remote Similarity |
NPD4458 |
Phase 2 |
0.5913 |
Remote Similarity |
NPD1063 |
Phase 2 |
0.5892 |
Remote Similarity |
NPD8250 |
Phase 2 |
0.5889 |
Remote Similarity |
NPD282 |
Approved |
0.5879 |
Remote Similarity |
NPD1119 |
Phase 2 |
0.5867 |
Remote Similarity |
NPD5321 |
Phase 3 |
0.586 |
Remote Similarity |
NPD2253 |
Discontinued |
0.5854 |
Remote Similarity |
NPD8373 |
Clinical (unspecified phase) |
0.5847 |
Remote Similarity |
NPD535 |
Approved |
0.5838 |
Remote Similarity |
NPD9606 |
Approved |
0.5833 |
Remote Similarity |
NPD353 |
Discontinued |
0.5826 |
Remote Similarity |
NPD5486 |
Discontinued |
0.5805 |
Remote Similarity |
NPD9607 |
Approved |
0.5782 |
Remote Similarity |
NPD2152 |
Clinical (unspecified phase) |
0.5765 |
Remote Similarity |
NPD5336 |
Phase 1 |
0.5765 |
Remote Similarity |
NPD5337 |
Phase 1 |
0.5747 |
Remote Similarity |
NPD5458 |
Discontinued |
0.5738 |
Remote Similarity |
NPD1058 |
Discontinued |
0.573 |
Remote Similarity |
NPD6112 |
Approved |
0.5729 |
Remote Similarity |
NPD2593 |
Clinical (unspecified phase) |
0.5727 |
Remote Similarity |
NPD4715 |
Clinical (unspecified phase) |
0.5727 |
Remote Similarity |
NPD4713 |
Clinical (unspecified phase) |
0.5727 |
Remote Similarity |
NPD4714 |
Approved |
0.5727 |
Remote Similarity |
NPD34 |
Approved |
0.5722 |
Remote Similarity |
NPD1127 |
Approved |
0.5722 |
Remote Similarity |
NPD1128 |
Approved |
0.5689 |
Remote Similarity |
NPD6763 |
Discontinued |
0.5672 |
Remote Similarity |
NPD7502 |
Clinical (unspecified phase) |
0.5665 |
Remote Similarity |
NPD9584 |
Phase 2 |
0.5652 |
Remote Similarity |
NPD209 |
Clinical (unspecified phase) |
0.5642 |
Remote Similarity |
NPD9084 |
Phase 2 |
0.5633 |
Remote Similarity |
NPD8271 |
Discontinued |
0.5611 |
Remote Similarity |
NPD281 |
Approved |
0.5607 |
Remote Similarity |
NPD8329 |
Phase 3 |
0.5603
|
Remote Similarity |
NPD6381 |
Phase 2 |